CGT analytics and digital integration – a symposium at CTAD 2024 with Dr. Stuart Curbishley

For more information, visit https://www.miltenyibiotec.com/lp/sta...

Dr. Stuart Curbishley, Chief Manufacturing and Development Officer at adthera bio, joins Miltenyi Biotec's Dmitry Fridman in a symposium on digital integration at the 2024 Cell Therapy Analytics Development Summit Europe.

Miltenyi Biotec is driving cell and gene therapy (CGT) analytics with innovative solutions to empower customers with seamless data exchange to and from all Miltenyi Biotec instruments. This "gateway", in Fridman's words, translates commands from a user's information systems to interrogate any Miltenyi Biotec instrument and seamlessly return the requested data.

Within the context of Curbishley's description of crucial bottlenecks complicating the advancement of CGT and adthera bio's digital integration strategy, the two experts discuss the importance of stepping away from today's time-consuming "paper-and-glass" method of data sharing and facilitating the digital transformation of CGT analytics.

Miltenyi Biotec is a global provider of products and services that empower biomedical discovery and advance cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Our technologies offer solutions for cellular research, cell therapy, and cell manufacturing. Our more than 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, cancer, hematology, and graft engineering. In our commitment to the scientific community, we also offer comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 4,700 employees in 23 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.